Study: Some anticoagulants more cost-effective than warfarin

04/10/2013 | MedPage Today (free registration)

The anticoagulants apixaban, dabigatran and rivaroxaban are more cost-effective than warfarin in the prevention of strokes among patients with nonvalvular atrial fibrillation, according to a study in Stroke: Journal of the American Heart Association. The costs analyzed in the review were associated with clinical events, visits with doctors, medicines, testing and adverse events.

View Full Article in:

MedPage Today (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Life Sciences Lawyer (3-5 years exp)
Ropes & Gray LLP
Boston, MA; San Francisco, CA; Silicon Valley, CA, MA
Director of Accreditation
Meridian Health Plan
Detroit, MI
Health Services Researcher
AARP
Washington, DC
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC